Current trends and promising clinical utility of IPSC-derived MSC (iMSC)

Shih Hwa Chiou, Han Kiat Alan Ong, Shih Jie Chou, A. F. Aldoghachi, Jit Kai Loh, Nalini Devi Verusingam, Yi Ping Yang*, Yueh Chien

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Mesenchymal stem cells (MSCs) differentiated from human induced pluripotent stem cells (iPSC) or induced MSC (iMSCs) are expected to address issues of scalability and safety as well as the difficulty in producing homogenous clinical grade MSCs as demonstrated by the promising outcomes from preclinical and clinical trials, currently ongoing. The assessment of iMSCs based in vitro and in vivo studies have thus far showed more superior performance as compared to that of the primary or native human MSCs, in terms of cell proliferation, expansion capacity, immunomodulation properties as well as the influence of paracrine signaling and exosomal influence in cell-cell interaction. In this chapter, an overview of current well-established methods in generating a sustainable source of iMSCs involving well defined culture media is discussed followed by the properties of iMSC as compared to that of MSC and its promising prospects for continuous development into potential clinical grade applications.

Original languageEnglish
Title of host publicationProgress in Molecular Biology and Translational Science
EditorsAkon Higuchi, Yinghong Zhou, Shih-Hwa Chiou
PublisherElsevier B.V.
Pages131-154
Number of pages24
ISBN (Print)9780443134111
DOIs
StatePublished - Jan 2023

Publication series

NameProgress in Molecular Biology and Translational Science
Volume199
ISSN (Print)1877-1173
ISSN (Electronic)1878-0814

Fingerprint

Dive into the research topics of 'Current trends and promising clinical utility of IPSC-derived MSC (iMSC)'. Together they form a unique fingerprint.

Cite this